In this video, Dr Richard Buick, Chief Scientific Officer at Fusion Antibodies, provides an update on the DR5 project.

• DR5 is a protein on cancer cells that, when activated, triggers tumour cell self-destruction

• Previous pharma attempts failed due to antibodies not being able to effectively cluster the receptor

• Fusion's antibody actively trimerises DR5, driving stronger cancer cell death than competitors including Amgen's Conatumumab

• Innovate UK-funded project in collaboration with Queen's University Belfast

• Preclinical data shows strong, specific cell death in colorectal cancer cells — with no effect when DR5 is removed, confirming mechanism of action

• Manufacturing cell lines being developed using Microfluidic technology, cutting timelines from 9 to 4 months

• Next step: in vivo testing, moving towards potential partnering or licensing